Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy

Trial Profile

Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 12 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 12 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 10 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top